Morgan Stanley analyst Sean Laaman has maintained their neutral stance on HALO stock, giving a Hold rating on July 16.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sean Laaman has given his Hold rating due to a combination of factors affecting Halozyme’s future performance. One of the primary concerns is the uncertainty surrounding the CMS draft pricing guidance, which could potentially impact the pricing negotiations for Halozyme’s combination products. This draft guidance poses a risk to the company’s long-term revenues, especially if their products are not exempt from the price negotiations expected to take effect in 2028.
Additionally, while Halozyme has raised its financial guidance for 2025, reflecting increased royalty revenues and partner orders, there remains a need for clarity on how regulatory updates will influence these projections. The company has forecasted total revenues and adjusted EBITDA for 2025, but the potential impact of regulatory changes and the need for updates on capital management and business development efforts contribute to the Hold rating. Investors are advised to monitor these developments closely as they could significantly affect Halozyme’s financial outlook.
Laaman covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Halozyme, and Jazz Pharmaceuticals. According to TipRanks, Laaman has an average return of 3.6% and a 56.90% success rate on recommended stocks.
In another report released on July 16, J.P. Morgan also maintained a Hold rating on the stock with a $60.00 price target.